Physician profile
Haley Meeks
NPI 1619549193
$4,770.13
in general payments reported to CMS, 2019-2025
27 companies · $917 in 2025
The $917 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.09 · 2022: $1,204 · 2023: $1,236 · 2024: $1,351 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,503.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $957.80 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $745.23 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $704.41 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $394.68 | 2022-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $339.75 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $233.10 | 2022-2023 | |
| Theratechnologies INC. | $203.07 | 2023-2025 | Trogarzo, Egrifta |
| Glaxosmithkline, LLC. | $195.82 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $180.55 | 2022-2025 | |
| Amgen INC. | $104.88 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.92 | 2022-2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $81.57 | 2021-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $72.22 | 2022-2023 | Hetlioz, Fanapt |
| Biohaven Pharmaceutical Holding Company LTD. | $69.30 | 2022 | |
| Merck Sharp & Dohme LLC | $63.38 | 2021-2023 | Belsomra, Januvia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $59.88 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $37.31 | 2023-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $33.77 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.89 | 2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $27.35 | 2024 | Abilify Asimtufii, Rexulti |
| Kowa Pharmaceuticals America, INC. | $26.57 | 2022-2023 | Seglentis |
| Ucb, INC. | $22.40 | 2025 | Bimzelx |
| Dexcom, INC. | $21.50 | 2023 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $20.27 | 2022 | |
| Almatica Pharma LLC | $18.52 | 2021 | |
| Tactile Systems Technology INC | $14.70 | 2025 | Flexitouch Plus, Nimbl |
| Supernus Pharmaceuticals, INC. | $14.29 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Meeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.